Liposomal nanomedicines in the treatment of prostate cancer

Cancer Treatment Reviews

Volumn 40, Issue 4, 2014, Pages 578-584

  Kroon, Jan ^a,b   Metselaar, Josbert M ^b   Storm, Gert ^b,c   van der Pluijm, Gabri ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Active targeting; Liposomes; Nanomedicine; Passive targeting; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; GELATINASE B; GEMCITABINE; INTERLEUKIN 6; MITOXANTRONE; PACLITAXEL; PREDNISONE; SIGMA OPIATE RECEPTOR; VASCULOTROPIN; ZOLEDRONIC ACID;

ANEMIA; APOPTOSIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; ENDOTHELIUM CELL; HUMAN; LEUKOPENIA; LIPOSOMAL DELIVERY; NANOMEDICINE; NEUTROPENIA; NONHUMAN; OSTEOCLAST ACTIVITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SAFETY; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

ACTIVE TARGETING; LIPOSOMES; NANOMEDICINE; PASSIVE TARGETING; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MALE; NANOMEDICINE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84896739817     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.10.005     Document Type: Review

References (66)

1. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012 Jul 20, 161(2):175-187. PubMed PMID: 21945285.
2. Arias JL. Liposomes in drug delivery: a patent review (2007-present). Expert Opin Ther Pat. 2013.
3. Slingerland M., Guchelaar H.J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012, 17(3-4):160-166. PubMed PMID: 21983329.
4. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013, PubMed PMID: 23880506.
5. Patterson S.G., Wei S., Chen X., Sallman D.A., Gilvary D.L., Zhong B., et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006, 25(45):6113-6122. PubMed PMID: 16652143.
6. de Barros A.L., Mota L., Soares D.C., de Souza C.M., Cassali G.D., Oliveira M.C., et al. Long-circulating, pH-sensitive liposomes versus long-circulating, non-pH-sensitive liposomes as a delivery system for tumor identification. J Biomed Nanotechnol 2013, 9(9):1636-1643. PubMed PMID: 23980511.
7. Kaasgaard T., Andresen T.L. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 2010, 7(2):225-243. PubMed PMID: 20095944.
8. Sawant R.R., Tochilin V.P. Challenges in development of targeted liposomal therapeutics. AAPS J 2012, 14(2):303-315. Pubmed Central PMCID: 3326155.
9. Fenske D.B., Chonn A., Cullis P.R. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008, 36(1):21-29. PubMed PMID: 18337218.
10. Maurer N., Fenske D.B., Cullis P.R. Developments in liposomal drug delivery systems. Expert opin Biol Ther 2001, 1(6):923-947. PubMed PMID: 11728226.
11. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760. PubMed PMID: 18654426.
12. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55(17):3752-3756. PubMed PMID: 7641188.
13. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156(4):1363-1380. Pubmed Central PMCID: 1876882.
14. Katsogiannou M., Peng L., Catapano C.V., Rocchi P. Active-targeted nanotherapy strategies for prostate cancer. Curr Cancer Drug Targets 2011, 11(8):954-965. PubMed PMID: 21861840.
15. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66(13):6732-6740. PubMed PMID: 16818648.
16. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(15):1502-1512. PubMed PMID: 15470213.
17. Carles J., Castellano D., Climent M.A., Maroto P., Medina R., Alcaraz A. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol 2012, 14(3):169-176. PubMed PMID: 22374419.
18. Deeken J.F., Slack R., Weiss G.J., Ramanathan R.K., Pishvaian M.J., Hwang J., et al. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 2013, 71(3):627-633. PubMed PMID: 23274395.
19. Hagtvet E., Roe K., Olsen D.R. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol 2011, 6:135. PubMed PMID: 21981945. Pubmed Central PMCID: 3193805.
20. Banerjee R., Tyagi P., Li S., Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004, 112(4):693-700. PubMed PMID: 15382053.
21. Chen X., Wang X., Wang Y., Yang L., Hu J., Xiao W., et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 2010, 145(1):17-25. PubMed PMID: 20307599.
22. Hagtvet E., Evjen T.J., Olsen D.R., Fossheim S.L., Nilssen E.A. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. J Drug Target 2011, 19(8):701-708. PubMed PMID: 21524240.
23. Eggen S., Afadzi M., Nilssen E.A., Haugstad S.B., Angelsen B., Davies Cde L. Ultrasound improves the uptake and distribution of liposomal Doxorubicin in prostate cancer xenografts. Ultrasound Med Biol 2013, 39(7):1255-1266. PubMed PMID: 23643054.
24. Jantscheff P., Esser N., Graeser R., Ziroli V., Kluth J., Unger C., et al. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate 2009, 69(11):1151-1163. PubMed PMID: 19399788.
25. Jantscheff P., Ziroli V., Esser N., Graeser R., Kluth J., Sukolinskaya A., et al. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clin Exp Metastasis 2009, 26(8):981-992. PubMed PMID: 19784785.
26. Bode C., Trojan L., Weiss C., Kraenzlin B., Michaelis U., Teifel M., et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep 2009, 22(2):321-326. PubMed PMID: 19578772.
27. Pinto A.C., Moreira J.N., Simoes S. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate 2011, 71(1):81-90. PubMed PMID: 20607721.
28. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337. PubMed PMID: 20587042. Pubmed Central PMCID: 2907344.
29. Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012, 7:49-60. PubMed PMID: 22275822. Pubmed Central PMCID: 3260950.
30. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55(2):408-413. PubMed PMID: 7812973.
31. Garde S.V., Forte A.J., Ge M., Lepekhin E.A., Panchal C.J., Rabbani S.A., et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007, 18(10):1189-1200. PubMed PMID: 17893520.
32. Rogers T.L., Holen I. Tumor macrophages as potential targets of bisphosphonates. J Tansl Med 2011, 9:177. PubMed PMID: 22005011. Pubmed Central PMCID: 3215187.
33. Miselis N.R., Wu Z.J., Van Rooijen N., Kane A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008, 7(4):788-799. PubMed PMID: 18375821.
34. Banciu M., Metselaar J.M., Schiffelers R.M., Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 2008, 10(2):108-117. PubMed PMID: 18283332. Pubmed Central PMCID: 2244685.
35. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16(27):2950-2960. PubMed PMID: 20722616.
36. Marra M., Salzano G., Leonetti C., Tassone P., Scarsella M., Zappavinga S., et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 2012, 30(1):302-309. PubMed PMID: 21741464.
37. Marra M., Salzano G., Leonetti C., Tassone P., Scarsella M., Zappavigna S., et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011, 7(6):955-964. PubMed PMID: 21453789.
38. Hiraoka K., Zenmyo M., Watari K., Iguchi H., Fotovati A., Kimura Y.N., et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008, 99(8):1595-1602. PubMed PMID: 18754872.
39. Kim S.W., Kim J.S., Papadopoulos J., Choi H.J., He J., Maya M., et al. Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 2011, 11(7):862-872. PubMed PMID: 21251905. Pubmed Central PMCID: 3086935.
40. Hengst V., Oussoren C., Kissel T., Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 2007, 331(2):224-227. PubMed PMID: 17150316.
41. Anada T., Takeda Y., Honda Y., Sakurai K., Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett 2009, 19(15):4148-4150. PubMed PMID: 19523821.
42. Wang G., Mostafa N.Z., Incani V., Kucharski C., Uludag H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res A. 2012, 100(3):684-693. PubMed PMID: 22213565.
43. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17(9):2941-2953. PubMed PMID: 10561374.
44. Sonoke S., Ueda T., Fujiwara K., Sato Y., Takagaki K., Hirabayashi K., et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008, 68(21):8843-8851. PubMed PMID: 18974128.
45. Leenders F., Mopert K., Schmiedeknecht A., Santel A., Czauderna F., Aleku M., et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 2004, 23(16):3303-3313. PubMed PMID: 15282551. Pubmed Central PMCID: 514518.
46. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008, 68(23):9788-9798. PubMed PMID: 19047158.
47. Pal A., Ahmad A., Khan S., Sakabe I., Zhang C., Kasid U.N., et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005, 26(4):1087-1091. PubMed PMID: 15754006.
48. Pei J., Zhang C., Gokhale P.C., Rahman A., Dritschilo A., Ahmad I., et al. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 2004, 15(3):243-253. PubMed PMID: 15014358.
49. Shao L., Tekedereli I., Wang J., Yuca E., Tsang S., Sood A., et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 2012, 18(24):6648-6657. PubMed PMID: 23052253. Pubmed Central PMCID: 3525716.
50. Xiang B., Dong D.W., Shi N.Q., Gao W., Yang Z.Z., Cui Y., et al. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 2013, 34(28):6976-6991. PubMed PMID: 23777916.
51. Bisanz K., Yu J., Edlund M., Spohn B., Hung M.C., Chung L.W., et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005, 12(4):634-643. PubMed PMID: 16039164.
52. Flaherty K.T., Malkowicz S.B., Vaughn D.J. Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. Am J Clin Oncol 2004, 27(2):136-139. PubMed PMID: 15057152.
53. Harris K.A., Harney E., Small E.J. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer 2002, 1(1):37-41. PubMed PMID: 15046711.
54. Montanari M., Fabbri F., Rondini E., Frassineti G.L., Mattioli R., Carloni S., et al. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori 2012 Nov, 98(6):696-701. PubMed PMID: 23389354.
55. Hubert A., Lyass O., Pode D., Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000, 11(2):123-127. PubMed PMID: 10789595.
56. Heidenreich A., Sommer F., Ohlmann C.H., Schrader A.J., Olbert P., Goecke J., et al. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 2004, 101(5):948-956. PubMed PMID: 15329902.
57. McMenemin R., Macdonald G., Moffat L., Bissett D. A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest New Drugs 2002, 20(3):331-337. PubMed PMID: 12201496.
58. Fossa S.D., Vaage S., Letocha H., Iversen J., Risberg T., Johannessen D.C., et al. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)-delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 2002, 36(1):34-39. PubMed PMID: 12002355.
59. Kouroussis C., Androulakis N., Vamvakas L., Kalykaki A., Spiridonakou S., Kentepozidis N., et al. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors. Oncology 2005, 69(3):202-207. PubMed PMID: 16127289.
60. Budman D.R., Calabro A., Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002, 13(10):1011-1016. PubMed PMID: 12439335.
61. Lotem M., Hubert A., Lyass O., Goldenhersh M.A., Ingber A., Peretz T., et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000, 136(12):1475-1480. PubMed PMID: 11115157.
62. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995, 13(7):1777-1785. PubMed PMID: 7602367.
63. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449. PubMed PMID: 14998846.
64. Liu C.Y., Xu J.Y., Shi X.Y., Huang W., Ruan T.Y., Xie P., et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 2013, 93(7):844-854. PubMed PMID: 23752129.
65. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141(1):39-51. PubMed PMID: 20371344.
66. Sturge J., Caley M.P., Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8(6):357-368. PubMed PMID: 21556025.